Sanofi-Aventis sends out Multaq warning letter
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis has confirmed to Scrip that it will be sending out a "Dear healthcare provider" letter to physicians informing them of liver function test abnormalities and hepatocellular injury reported in patients treated with Multaq (dronedarone), including two case reports of acute liver failure requiring transplantation.